AO-176 for Tumors, Solid

Phase-Based Estimates
1
Effectiveness
1
Safety
Oklahoma University, Stephenson Cancer Center, Oklahoma City, OK
AO-176 - Drug
Eligibility
18+
All Sexes
Eligible conditions
Tumors, Solid

Study Summary

This study is evaluating whether a drug may help treat solid tumors.

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether AO-176 will improve 3 primary outcomes and 3 secondary outcomes in patients with Tumors, Solid. Measurement will happen over the course of Up to 12 months.

Up to 12 months
AO-176 + paclitaxel anti-tumor activity assessed by changes in response criteria
AO-176 + pembrolizumab anti-tumor activity assessed by changes in response criteria
AO-176 anti-tumor activity assessed by changes in response criteria
Safety of AO-176 and paclitaxel assessed by adverse events and laboratory abnormalities
Safety of AO-176 and pembrolizumab assessed by adverse events and laboratory abnormalities
Safety of AO-176 assessed by adverse events and laboratory abnormalities

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

6 Treatment Groups

No Control Group
AO-176 Dose Escalation

This trial requires 183 total participants across 6 different treatment groups

This trial involves 6 different treatments. AO-176 is the primary treatment being studied. Participants will be divided into 6 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

AO-176 Dose Escalation
Drug
Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
AO-176 + Paclitaxel Dose Escalation
Drug
Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
AO-176 + Pembrolizumab Dose Escalation
Drug
Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
AO-176 + Paclitaxel Dose Expansion
Drug
Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176 + paclitaxel.
AO-176 Dose Expansion
Drug
Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
AO-176 + Pembrolizumab Dose Expansion
Drug
Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176 + pembrolizumab.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 12 months for reporting.

Closest Location

Oklahoma University, Stephenson Cancer Center - Oklahoma City, OK

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Select advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist, or is no longer effective
is the most common type of ovarian cancer show original
The key inclusion criteria for the study are: 1 show original
Endometrial carcinoma
is cancer that doesn't respond to treatments that lower testosterone levels show original
Non-small cell lung adenocarcinoma
Papillary thyroid carcinoma
Malignant mesothelioma (pleural or peritoneal)
Gastroesophageal adenocarcinoma
is the most common type of cancer in this area show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of tumors, solid?

Add answer

Tumors have different characteristics including: color, site, tenderness, and size. The signs of tumors is an important part of a physical exam. On physical examination, palpation of tumor in the skin and subcuticular tissues, pain, and location of the new wound may lead to a differential diagnosis. These parameters can be quantified and objectively measured to help with diagnosis: palpable tumor, location of nodule, wound appearance, color, pain, and size. Also, an ultrasound scan can be done to quantify a lesion size or to confirm a malignancy.

Unverified Answer

What causes tumors, solid?

Add answer

Tumors are formed from the unregulated growth of cells within a tumor; this is due to a combination of mutations and environmental stress. The most common cancer is skin carcinoma, while the most likely tumor in the brain is brain tumor. Tumor formation can be caused when cells that grow outside of the natural tissue boundaries fail to differentiate, become more sensitive to growth factors, or start dividing more rapidly than normal tissue. If there is growth in the tumor, the body's defense system stops the tumor's growth until the cancer is in a location that prevents the tumor from blocking its blood supply. This can cause the tumor to become hard and misshapen.

Unverified Answer

How many people get tumors, solid a year in the United States?

Add answer

There are more people with tumors, solids than people with tumors, solids each year in the United States as compared to other cancer types combined (i.e., 3.7 million vs. 2.6 million). This is mainly because people with tumors, solids have more people with tumors, solids than other types of cancer combined, such as 4.8 million vs. 3.5 million. While the rate of new cases of tumors and tumors, solids annually in the United States are 0.8 and 0.2 per 1,000 respectively, the number of people afflicted with these two solid malignancies combined is very high, especially when compared to cancer in general (14 million people diagnosed with cancer annually).

Unverified Answer

What is tumors, solid?

Add answer

Tumors are solid tumors that can form in and around the blood and lymph vessels and can stop the flow of blood and lymph by blocking off the blood vessels. They can be malignant (cancer) or benign but can also have a benign form. Tumors can be benign or malignant.

Unverified Answer

Can tumors, solid be cured?

Add answer

Tumors, solid cannot be cured. Tumors must be treated so that they do not grow, and become symptomatic. A wide variety of methods can be employed to reduce tumor size and minimize its symptoms. If not all of these methods are unsuccessful, however, then tumors, solid cannot be cured.

Unverified Answer

What are common treatments for tumors, solid?

Add answer

A variety of treatments are used to help control certain types of cancer in the body. Common treatments include surgery, radiation, chemotherapy, targeted therapy and immunotherapy depending on the treatment needed for a specific cancer.

Unverified Answer

How serious can tumors, solid be?

Add answer

While it may look calm on the surface, tumor progression can sometimes manifest itself in severe symptoms. In one case study, a 50-year-old man presented with fever and symptoms of respiratory distress. After initial evaluation at an outside clinic, his diagnosis of bronchitis and pneumonia was reinforced. He was treated with antibiotics for both infections, and continued to complain of fever, and discomfort in chest. He was again evaluated by physicians at the clinic and admitted to the emergency Department. Imaging of his chest x-rays revealed a left upper-lobe pulmonary tumor. The case was further evaluated and found to be unresectable due to significant burden to the left hemiparesis.

Unverified Answer

What are the common side effects of ao-176?

Add answer

These side effects include headache and dizziness due to diclofenac. However the side effects from Ao-176 were more common and severe. If you are considering using diclofenac, you should definitely keep in mind that ao-176 can make you dizzy and drowsy because of dizziness, diclofenac is not approved by the U.S. Food & Drug Administration for ao-176's use. [Power (https://www.withpower.

Unverified Answer

What does ao-176 usually treat?

Add answer

Ao-176 is a promising anticancer drug candidate. Combining Ao-176 with RT, RT + AZA, or VAC chemotherapy can significantly enhance the therapeutic index of Ao-176. This combination, in conjunction with local anti-tumor effect, should be further explored as a viable treatment option for patients with advanced NSCLC and/or advanced rectal cancer.

Unverified Answer

Does tumors, solid run in families?

Add answer

Familial breast, colorectal, and [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer) are uncommon. When present, these cancers tend to occur late in life, especially among individuals who have only two other family members affected by the same tumor. The lack of associations between solid tumor incidence and cancer family history suggests that genetic risk factors in common with breast and colon cancers may play a role in solid tumor risk.

Unverified Answer

Have there been any new discoveries for treating tumors, solid?

Add answer

[Treatment of tumors, solid, and the advancements in the scientific understanding of the mechanisms of tumor cells] have shown that different treatments are now available to treat tumors, solid(es). These techniques have shown positive results as well for many patients. In order to find a clinical trial that helps your tumors, solid, check outPower.. As discussed earlier, for new clinical trials of [tumor, solid], search for the Power website[https://www.withpower.

Unverified Answer

Is ao-176 safe for people?

Add answer

Ao-176 may be used safely at doses of 600 and 1000 mg per week IV for 6 months as monotherapy in people with solid tumor metastases following radiotherapy, radiation related GI complications, or radiation induced GI/HNS related long term complications.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Tumors, Solid by sharing your contact details with the study coordinator.